Safety assessment of Granulocyte Colony Stimulating Factor:ior LeukoCIM in oncohematologic patients.Phase IV study.
Phase 4
Completed
- Conditions
- eutropenia secondary to Chemotherapy and/or Radiotherapy in oncohematologic patients .
- Registration Number
- RPCEC00000083
- Lead Sponsor
- Center of Molecular Immunology(CIM)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1.Patients who met the diagnostic criteria and/or condition of use. 2.Patients with cytologic diagnosis and/or histologically confirmed cancer of any location that are receiving QT and/or RT. 3.Patients of all ages and both sexes.
Exclusion Criteria
1.Patients with known hypersensitivity to products derived from cells of E.Coli or other preparations of rG-CSF. 2.Patients pregnant or breastfeeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Granulocyte Colony Stimulating Factor in oncohematologic patients with chemotherapy-induced neutropenia?
How does ior LeukoCIM compare to other G-CSF agents like filgrastim in managing neutropenia post-chemotherapy?
What biomarkers are associated with response to G-CSF therapy in patients with eutropenia following radiotherapy?
What are the potential adverse events of long-term G-CSF use in oncohematologic patients and how are they managed?
What are the current combination therapies involving G-CSF for hematologic malignancies and how do they enhance efficacy?